EVALUATION OF IMMUNE-BASED THERAPIES FOR AIDS USING ANIMAL MODELS RFP AVAILABLE: NIAID-DAIDS-92-15 (see erratum not92-019) P.T. 34 Keywords: AIDS Immunotherapy Disease Model National Institute of Allergy and Infectious Diseases The Developmental Therapeutics Branch, Basic Research and Development Program, Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), has a requirement for the evaluation of immune-based therapies for AIDS using animal models. This procurement consists of two parts that seek testing capabilities for immune-based therapies that target different types of immune deficiencies seen in HIV infection and AIDS. The two parts are entitled, "Part A - Evaluation of Immune-Based Therapies to Augment or Normalize Immune Function" and "Part B - Evaluation of Multipotent Stem Cell Reconstitution as a Therapy to Restore Immune Cell Deficits". "Part A" of this procurement will provide for the evaluation of immune-based therapies in an established small-animal model, alone or in combination with other therapies, for their capacity to augment host-defense mechanisms or otherwise ameliorate immune dysfunctions characteristic of HIV infection. Emphasis will be placed on aspects of immune-based therapies, i.e., mechanism of action, optimal scheduling, identification of quantifiable parameters related to in vivo efficacy, potential for positive or negative interaction between immune-based and anti-retroviral therapies, and the potential of immune-based therapies to upregulate virus expression. An established and validated animal model is required for Part A. "Part B" of this procurement will provide for development, validation, and testing of a model in which an immunodeficient animal is reconstituted with a source of human multipotent stem cells that can re-establish the immune system and that may also be genetically modified to resist subsequent infection with HIV-1. The offeror shall, at the time of proposal, have identified an animal system to be developed and validated and a source of human multipotent stem cells. These capabilities are required by the Division of AIDS, NIAID, in its efforts to develop immune-based therapies for human subjects infected with HIV-1. There will be separate work statements and competitive ranges established for each part. Offerors may respond to one or more parts. It is anticipated that one or more awards will be made for Part A and one award will be made for Part B. If more than one award is made for Part A, the Government reserves the right to make only one award per animal model. This NIAID-sponsored project will take approximately five years to complete. A cost-reimbursement contract is anticipated. This is an announcement for an anticipated Request for Proposal (RFP). RFP NIAID-DAIDS-92-15 shall be issued on or about January 20, 1992, with a closing date tentatively set for March 20, 1992. Requests for the RFP shall be directed in writing to: Cyndie Cotter Contract Management Branch National Institute of Allergy and Infectious Diseases Solar Building, Room 3C-07 6003 Executive Boulevard Bethesda, MD 20892 To receive a copy of the RFP, supply this office with two self-addressed labels. All responsible sources may submit a proposal that will be considered. This announcement does not commit the Government to award a contract. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||